He Ministry of Health has approved financing in the National Health System for the first and only treatment that provides an effective and sustained reduction in cholesterol with two doses a year.
As reported by the pharmacist Novartis, inclisiranthe active ingredient of Leqvialready approved in Europe, provides an effective and sustained reduction in cholesterol in 54% of patients with atherosclerotic cardiovascular disease, added to the maximum tolerated dose of statins and with maintenance administration using subcutaneous injection twice a year.
The drug interferes with RNA and limits the production of LDL (bad cholesterol) levels. With its administration, patients with hypercholesterolemia can regulate their blood cholesterol levels below 100 mg/dl.
Cholesterol is a natural fat that circulates through the blood, but if levels are higher than 200 mg/dl it can cause cardiovascular diseases.
In Spain, cardiovascular diseases are the leading cause of death. According to data from the INE, 119,196 people died in 2021 due to these diseases, 26.4% of the total deaths.